David Maris

David Maris Recent News

Forget Trump Or Congress, Amazon May Be The Biggest Threat To Drug Pricing
5 Takeaways For Valeant Investors As Ackman Exits
Concerns From Valeant's 10-K: $8 Billion Of Asset Sales Is Now A Mirage
Valeant Shares Carry Too Much Risk To Be Recommended As An Investment: Wells Fargo
Pot, Meet Kettle: Wells Fargo Says Valeant's Stock Too Risky In Light Of Potential Fraud Charges
The Street Is Underestimating Valeant's Potential Downside From Legal Woes
Valeant Keeps Raising Drug Prices, Stock Still Carries Too Much Risk: Wells Fargo
Wells Fargo On Valeant: Things Can Always Get Worse
Valeant's Debt In 2020 'May Be Too High A Hurdle'
Wells Fargo's Analyst Discusses Valeant's 'Apology Tour'
Valeant's Default Notice Should Keep Investors On Sidelines: Wells Fargo Keeps Underperform Rating
Left: I No Longer Have Valeant Short
Valeant Gets Closer To Left's $50 Target After New Accounting Fears
UPDATE: Valeant Plunges 7% After Bearish Wells Fargo Report
UPDATE: The Problem With Valeant's Guidance, According To Wells Fargo
Valeant Has 42% Downside And Too Many Questions, Wells Fargo Warns
Top Takeaways From BMO's Specialty Pharma Day
Is Teva A Better Target For Mylan Than Perrigo? 2 Analysts Share Their Thoughts
Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma
UPDATE: BMO Capital Markets Reiterates on Teva Pharmaceutical Industries Ltd. Following Announcement of CEO Resignation
UPDATE: BMO Capital Markets Upgrades Forest Laboratories as Underperformance is Unlikely While Street Awaits New Plan

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved